Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12931880 | 0.98 | EPHX2 (1.00) | EPHX2ALDH1A1 | |
| SCHEMBL19966024 | 0.88 | EPHX2 (0.77) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL31276295 | 0.85 | EPHX2 (0.72) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL12931878 | 0.84 | EPHX2 (1.00) | EPHX2ALDH1A1 | |
| SCHEMBL31275669 | 0.84 | EPHX2 (0.75) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL30927840 | 0.84 | EPHX2 (0.70) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL29129704 | 0.84 | EPHX2 (0.70) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL31529425 | 0.83 | EPHX2 (0.69) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL30927839 | 0.83 | EPHX2 (0.73) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL30927841 | 0.83 | EPHX2 (0.73) | EPHX2ALDH1A1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-2308871-A1 | Substituted indole compounds and their use as 5-HT6 receptor modulators | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| EP-1648445-B1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | ESTEVE LABOR DR (ES) | 2009-06-03 | — | — | EP | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| CN-101068809-A | Substituted indole compounds and their use as 5-ht6 receptor modulators | ESTEVE LABOR DR (ES) | 2007-11-07 | — | — | CN | disclosed |
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-13 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070032520-A1 | Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-02-08 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| EP-1660131-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-31 | — | — | EP | disclosed |
| EP-1648468-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1648445-A1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1632491-A1 | Substituted indole compounds and their use as 5-HT6 receptor modulators | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005014000-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005013977-A1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014045-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | HTR6, TPH1, TPH2 | EPHX2 3167/4885ALDH1A1 1241/4885MEN1 1818/4885 |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | EPHX2 2944/4885ALDH1A1 3499/4885MEN1 1677/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | EPHX2 2944/4885ALDH1A1 3499/4885MEN1 1677/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | EPHX2 2943/4885ALDH1A1 3880/4885MEN1 1861/4885 |
| US-20070032520-A1 | Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, HTR5A, TPH1 | EPHX2 2550/4885ALDH1A1 1252/4885MEN1 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.